Mostrar el registro sencillo del ítem

dc.contributor.authorIglesias Rey, Ramón
dc.contributor.authorCustodia Malvido, Antía
dc.contributor.authorAlonso-Alonso, M.L.
dc.contributor.authorLópez-Dequidt, I.
dc.contributor.authorRodríguez Yáñez, Manuel 
dc.contributor.authorPumar Cebreiro, José Manuel 
dc.contributor.authorCastillo Sánchez, José 
dc.contributor.authorSobrino Moreiras, Tomas 
dc.contributor.authorCampos Pérez, Francisco 
dc.contributor.authorDa Silva Candal, Andrés Alexander
dc.contributor.authorHervella Lorenzo, Pablo
dc.date.accessioned2025-08-14T11:53:01Z
dc.date.available2025-08-14T11:53:01Z
dc.date.issued2022
dc.identifier.citationIglesias-Rey R, Custodia A, Alonso-Alonso ML, López-Dequidt I, Rodríguez-Yáñez M, Pumar JM, et al. The Smoking Paradox in Stroke Patients Under Reperfusion Treatment Is Associated With Endothelial Dysfunction. Frontiers in Neurology. 2022;13.
dc.identifier.issn1664-2295
dc.identifier.otherhttps://portalcientifico.sergas.gal/documentos/626d90863541a83b39a1cb58*
dc.identifier.urihttp://hdl.handle.net/20.500.11940/20441
dc.description.abstractObjective: This study aimed to explore the association between smoking habit and the serum levels of soluble tumor necrosis factor-like weak inducer of apoptosis (sTWEAK), in relation with the functional outcome of patients with acute ischemic stroke undergoing reperfusion treatment. Methods: Observational and retrospective study of a series of patients with acute ischemic stroke subjected to reperfusion treatments. Clinical, analytical, and neuroimaging parameters were analyzed. The main endpoint was the functional outcome at 3 months, measured by the modified Ranking Scale (mRS). Logistic regression models were used to analyze the association between smoking and sTWEAK levels with functional outcome and leukoaraiosis. Results: The results showed that smoking habit was associated with a good functional outcome at 3 months in patients with stroke (OR: 3.52; 95% CI: 1.03-11.9; p = 0.044). However, this independent association was lost after adjusting by sTWEAK levels (OR 1.73; 95% CI: 0.86-13.28; p = 0.116). sTWEAK levels were significantly lower in smoker patients [4015.5 (973.66-7921.83) pg/ml vs. 5,628 (2,848-10,202) pg/ml, p < 0.0001], while sTWEAK levels were significantly higher in patients with poor functional outcomes at 3 months [10,284 (7,388-13.247) pg/ml vs. 3,405 (2,329-6,629) pg/ml, p < 0.0001]. Conclusion: The decrease in sTWEAK levels was associated with a good functional outcome in smoker patients with stroke undergoing reperfusion therapy.en
dc.description.sponsorshipFunding This study was partially supported by grants from the Spanish Ministry of Science and Innovation (SAF2017-84267-R; PDC2021-121455-100), the Xunta de Galicia (Axencia Galega de Innovacion-GAIN; Conselleria de Cultura, Educacion e Universidade: IN607A2018/3), the Instituto de Salud Carlos III (ISCIII) (PI17/00540; PI17/01103; PI20/01014; PI21/01256; AC21_2/00014; RETICS-INVICTUS PLUS - RD16/0019/0001; RICORS ICTUS - RD21/0006/0003), co funded by European Union, FEDER program. Furthermore, TS (CPII17/00027) and FC (CPII19/00020) are recipients of research contracts from the Miguel Servet Program of Instituto de Salud Carlos III. AS-C (CD20/00054) recipient of Sara Borrell grant funded by Instituto de Salud Carlos III and co-funded by European Union. The sponsors did not participate in the study design, collection, analysis, or interpretation of the data, in writing the report, or in the decision to submit the paper for publication.en
dc.language.isoeng
dc.rightsAtribución 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.titleThe Smoking Paradox in Stroke Patients Under Reperfusion Treatment Is Associated With Endothelial Dysfunction*
dc.typeArticleen
dc.authorsophosIglesias-Rey, P. R.
dc.authorsophosCustodia, A.
dc.authorsophosAlonso-Alonso, M. L.
dc.authorsophosLópez-Dequidt, I.
dc.authorsophosRodríguez-Yáñez, M.
dc.authorsophosPumar, J. M.
dc.authorsophosCastillo, J.
dc.authorsophosSobrino, T.
dc.authorsophosCampos, F.
dc.authorsophosSilva-Candal, A. D.
dc.authorsophosHervella
dc.identifier.doi10.3389/fneur.2022.841484
dc.identifier.sophos626d90863541a83b39a1cb58
dc.issue.numbernull
dc.journal.titleFrontiers in Neurology*
dc.page.initialnull
dc.relation.projectIDSpanish Ministry of Science and Innovation [SAF2017-84267-R, PDC2021-121455-100]; Xunta de Galicia (Axencia Galega de Innovacion-GAIN) [IN607A2018/3]; Instituto de Salud Carlos III (ISCIII) [PI17/00540, PI17/01103, PI20/01014, PI21/01256, AC21_2/00014, RD16/0019/0001, RD21/0006/0003]; European Union [CPII17/00027, CPII19/00020]; Miguel Servet Program of Instituto de Salud Carlos III [CD20/00054]; Instituto de Salud Carlos III - European Union
dc.relation.publisherversionhttps://www.frontiersin.org/articles/10.3389/fneur.2022.841484/pdf;https://www.frontiersin.org/journals/neurology/articles/10.3389/fneur.2022.841484/pdfes
dc.rights.accessRightsopenAccess
dc.subject.keywordAS Santiagoes
dc.subject.keywordIDISes
dc.subject.keywordCHUSes
dc.subject.keywordAS Coruñaes
dc.subject.keywordINIBICes
dc.typefidesArtículo Científico (incluye Original, Original breve, Revisión Sistemática y Meta-análisis)es
dc.typesophosArtículo Originales
dc.volume.number13


Ficheros en el ítem

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución 4.0 Internacional
Excepto si se señala otra cosa, la licencia del ítem se describe como Atribución 4.0 Internacional